Experienced in Peripheral T-Cell Lymphoma

Dr. Milos D. Miljkovic

Internal Medicine
2401 W Belvedere Ave, 
Baltimore, MD 
Experienced in Peripheral T-Cell Lymphoma
2401 W Belvedere Ave, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Milos Miljkovic is a primary care provider, practicing in Internal Medicine in Baltimore, Maryland. Dr. Miljkovic is rated as an Experienced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are T-Cell Lymphoma, Non-Hodgkin Lymphoma, Adult T-Cell Leukemia, and Myasthenia Gravis.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 2 clinical trials in the study of Peripheral T-Cell Lymphoma.

Specialties
Internal Medicine
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

2401 W Belvedere Ave, Baltimore, MD 21215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Diagnostic test, Drug, Procedure
Study Drugs: Romidepsin, Lenalidomide, CC-486, Dexamethasone
Study Phase: Phase 1
Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection
Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection
Enrollment Status: Completed
Publish Date: March 21, 2023
A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: November 04, 2022
Intervention Type: Drug
Study Drugs: CC-486 (5-azacitidine), Duvelisib, Romidepsin, Doxorubicin
Study Phase: Phase 1
A Phase 1 Study of Interleukin-15 in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
A Phase 1 Study of Interleukin-15 in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Biological, Drug
Study Drugs: rhIL-15, Avelumab
Study Phase: Phase 1
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
Enrollment Status: Completed
Publish Date: April 29, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Enrollment Status: Terminated
Publish Date: March 22, 2022
Intervention Type: Biological, Drug
Study Drugs: rhIL-15, Obinutuzumab
Study Phase: Phase 1
View 5 Less Clinical Trials

57 Total Publications

Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis.
Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis.
Journal: Annals of clinical and translational neurology
Published: July 05, 2025
Similar Doctors
Experienced in Peripheral T-Cell Lymphoma
Dr. Christopher J. Melani
Internal Medicine
Experienced in Peripheral T-Cell Lymphoma
Dr. Christopher J. Melani
Internal Medicine
601 N Caroline St, 7th Floor, Suite A, 
Baltimore, MD 
 (5.2 miles away)
410-955-2817
Languages Spoken:
English

Christopher Melani is a primary care provider, practicing in Internal Medicine in Baltimore, Maryland. Dr. Melani is rated as a Distinguished provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Lymphomatoid Granulomatosis, Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, and Non-Hodgkin Lymphoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Miljkovic's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile